АBАigerim Baubekova

Аigerim Baubekova

*This is an algorithmically generated author record based on publicly available information.

Аigerim Baubekova has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RETROSPECTIVE ANALISIS OF POST- COVID SYNDROME OF CHILDREN AFTER SARS-COV-2

    by А.а. Zhamankulov, Аigerim Baubekova, Мarina Morenko, Rafail Rozenson, Madina Gatauova, Nurlan Utelbaev, Saule Maukayeva, Saulesh Apbassova, N.ZH. Chaizhunusova, Zhanargyl Smailova

    Introduction. At the end of December 2019, an outbreak of pneumonia of unknown origin occurred in the city of Wuhan, China. The outbreak was believed to be linked to a local seafood market. In early January 2020, during investigations, a new strain of coronavirus was identified, initially named 2019-nCoV. On February 11, 2020, the virus was officially named SARS-CoV-2, and the disease it causes was named COVID-19. On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic as the virus rapidly spread worldwide. Research Objective:To study the clinical and laboratory features of post-COVID syndrome in healthy children who have had SARS-CoV-2. Materials and Methods: A retrospective analysis of 516 medical records and outpatient charts of children who had contracted coronavirus infection between February and August 2020 was conducted. The study included demographic characteristics, clinical manifestations, and laboratory parameters. Statistical analysis was performed using standard biomedical statistical methods. Quantitative variables were presented as mean ± standard deviation (SD), and categorical variables as percentages. Differences were considered statistically significant at p < 0.05. Research Results:A parental survey of children who had recovered from COVID-19 revealed post-COVID-19 syndrome in 33.8% of cases. The predominant symptoms included fatigue, persistent cough, impaired concentration, headaches, and loss of taste and/or smell. Laboratory findings demonstrated reduced levels of vitamin D, leukocytes, lymphocytes, hemoglobin, and ferritin; elevated C-reactive protein (CRP), IgE, and erythrocyte sedimentation rate (ESR); and the presence of anti-SARS-CoV-2 antibodies in 90.2% of the children. Conclusions: Рost-COVID-19 syndrome developed in 33.8% of children following mild or moderate COVID-19, and was characterized by asthenic, respiratory, and cognitive components, accompanied by inflammatory and immunological alterations in laboratory parameters. Введение. В конце декабря 2019 года в городе Ухань, Китай, произошла вспышка пневмонии неизвестного происхождения. Считается, что вспышка была связана с местным рынком морепродуктов. В ходе исследований, проведенных в начале января 2020 года, был идентифицирован новый штамм коронавируса, первоначально названный 2019-nCoV. 11 февраля 2020 года вирус был официально назван SARS-CoV-2, а вызываемое им заболевание получило название COVID-19. 11 марта 2020 года Всемирная организация здравоохранения (ВОЗ) объявила о пандемии COVID-19, поскольку вирус быстро распространялся по всему миру. Цель исследования: изучить особенности клинико-лабораторного течения постковидного синдрома у здоровых детей, перенесших SARS-CoV-2 Материалы и методы: Проведен ретроспективный анализ 516 историй болезни и амбулаторных карт детей, перенесших коронавирусную инфекцию в период с февраля по август 2020 года. Анализ включал демографические характеристики, клинические проявления и лабораторные показатели. Статистическая обработка данных проводилась с использованием стандартных методов биомедицинской статистики. Количественные показатели представлены в виде среднего значения (Mean) ± стандартного отклонения (SD), качественные показатели — в процентах. Статистически значимыми считались различия при p < 0,05. Результаты исследования: Опрос родителей детей, перенёсших COVID-19, выявил постковидный синдром у 33,8% из них. Основные симптомы: слабость, остаточный кашель, снижение концентрации, головные боли, потеря вкуса/обоняния. Лабораторно отмечены снижение витамина D, лейкоцитов, лимфоцитов, гемоглобина, ферритина; повышение СРБ, IgE, СОЭ; антитела к SARS-CoV-2 – у 90,2%. Выводы: Таким образом, у 33,8 % детей, перенесших COVID-19 в лёгкой или среднетяжёлой форме, развивается постковидный синдром, характеризующийся астеническим, респираторным и когнитивным компонентами на фоне воспалительных и иммунологических изменений лабораторных показателей. Кіріспе. 2019 жылдың желтоқсан айының соңында Қытайдың Ухань қаласында шығу тегі белгісіз пневмонияның өршуі болды. Ауру жергілікті теңіз өнімдері нарығымен байланысты деп саналады. 2020 жылдың қаңтар айының басында жүргізілген зерттеулер бастапқыда 2019-nCoV деп аталатын...

  • Open Access

    UNDERSTANDING OF RECURRENT RESPIRATORY INFECTIONS IN CHILDREN AT THE PRESENT STAGE. REVIEW.

    by Zhamankulov A.A., Rozenson R.I., Morenko M.A., Maukaeva S.B., Gani B., Syzdykova M.M., Baubekova A.A.

    Introduction.Recurrent respiratory infections represent a significant burden on both individuals and healthcare systems worldwide. These infections, characterized by repeated episodes of upper and lower respiratory tract infections, are a common cause of morbidity and mortality in all age groups. The impact of recurrent respiratory infections extends beyond the physical symptoms experienced by affected individuals, often resulting in impaired quality of life, increased healthcare utilization, and economic costs. Aim. To study the features of recurrent respiratory infections in children, based on research data from the current literature in this field. Search strategy. The study was conducted using databases such as UpToDate, PubMed, Embase, Cochrane Library, and the Google Scholar search engine. The literature search spanned 9 years, from 2015 to 2024 inclusively. Original articles, randomized controlled trials, systematic reviews, and meta-analyses were included in the study. Results and conclusions.Understanding the underlying causes and mechanisms behind recurrent respiratory infections is crucial for effective management and prevention strategies. Managing recurrent respiratory infections is a complex task that requires a multifaceted approach. This review article has provided an overview of the various factors contributing to these infections, including host immune response, microbial pathogens, and environmental factors. Введение. Рецидивирующие респираторные инфекции представляют собой значительное бремя, как для отдельных людей, так и для систем здравоохранения во всем мире. Эти инфекции, характеризующиеся повторными эпизодами инфекций верхних и нижних дыхательных путей, являются распространенной причиной заболеваемости и смертности во всех возрастных группах. Последствия рецидивирующих респираторных инфекций выходят за рамки обычных симптомов, испытываемых пациентами, и часто приводят к ухудшению качества жизни, увеличению числа обращений за медицинской помощью и несут экономические затраты. Цель. Изучить особенности течения рецидивирующих респираторных инфекции у детей, на основании исследований данных современной литературы в этой области. Стратегия поиска. Исследование проводилось с использованием баз данных, таких как UpToDate, PubMed, Embase, Cochrane Library и поисковой системы Google Scholar. Литературный поиск охватывал период в 9 лет, с 2015 по 2024 год включительно. В исследование были включены оригинальные статьи, рандомизированные контролируемые исследования, систематические обзоры и мета-анализы. Результат и заключение. Понимание причин и механизмов, лежащих в основе рецидивирующих респираторных инфекций, имеет решающее значение для разработки эффективных стратегий лечения и профилактики. Лечение рецидивирующих респираторных инфекций - сложная задача, требующая многогранного подхода. В данном обзоре были представлены различные факторы, способствующих развитию респираторных инфекций, включая иммунный, микробные патогены и факторы окружающей среды. Кіріспе. Қайталанатын респираторлық инфекциялар бүкіл әлем бойынша жеке адамдарға да, денсаулық сақтау жүйесіне де айтарлықтай салмақ түсіреді. Жоғарғы және төменгі тыныс жолдарының инфекцияларының қайталанатын эпизодтарымен сипатталатын бұл инфекциялар барлық жас топтарындағы аурушаңдық пен өлімнің жалпы себебі болып табылады. Қайталанатынреспираторлық инфекциялардың әсері зардап шеккен адамдарда кездесетін физикалық белгілерден асып түседі, бұл көбінесе өмір сапасының нашарлауына, денсаулық сақтауды пайдаланудың жоғарылауына және экономикалық шығындарға әкеледі. Мақсат. Осы саладағы заманауи әдебиеттердің деректерін зерттеу негізінде балалардағы қайталанатынреспираторлық инфекциялардың ерекшеліктерін зерттеу. Іздеу стратегиясы. Зерттеу UpToDate, PubMed, Embase, Cochrane Library және Google Scholar іздеу жүйесі сияқты мәліметтер базасын қолдана отырып жүргізілді. Әдеби іздеу 2015 жылдан 2024 жылға дейінгі 9...

  • Open Access

    Specific features of the immune status of patients with bronchial asthma and COVID-19.

    by Айгерим Баубекова, Рафаил Розенсон

    Aim: to study the specific features of changes in the immune status of patients with bronchial asthma and COVID-19 Materials and methods: Study date: 08.2021-04.22. Study design: a review. A literature review was conducted in the PubMed, Scopus, Web of Science, MEDLINE, EMBASE, Cochrane Library databases, as well as a manual search for suitable articles. We analyzed immunological differences that may influence the pathophysiological process in patients with COVID-19 and asthma, including immunoglobulins, interferons, and local immune cells. Results: Through a study of 39 studies, including retrospective analyses, it was found that it is still unknown whether the asthma phenotype contributes to some protection of patients from COVID-19. Several immune differences have been found between COVID-19 patients with and without comorbid asthma: decreased levels of pro-inflammatory cytokines (e.g., IL-1β, TNF-α, IL-6, and IL-12), impaired production of type I and III interferons ( IFN-α, IFN-β, IFN-λ), which is a priority produced to fight the COVID-19 virus. Conclusions: Several of the research that have been reported so far are retrospective and do not differentiate between asthma phenotypes. Extensive therapeutic and immunological markers are severely lacking. To obtain a better knowledge of the immunological and metabolic link between COVID-19 and asthma, comprehensive endotyping of individuals with COVID-19 and asthma would be necessary. Furthermore, further information on the transcriptional and translational level of receptors modulation is needed at the level of virus-host contacts in relation to the virus's cellular entrance process. Furthermore, longterm prospective investigations are lacking. Additional knowledge on COVID-19 in asthmatic and allergy individuals is fast becoming available. Recent asthma treatment guidelines in the framework of COVID-19 should not be modified, according to current thinking. If indicated, patients will receive pharmacological therapy based on guidelines, including ICSs and biological treatments.